NasdaqGS - Nasdaq Real Time Price USD

ImmunityBio, Inc. (IBRX)

7.04 -0.61 (-7.97%)
At close: 4:00 PM EDT
7.05 +0.01 (+0.14%)
After hours: 5:48 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
302.00
622.00
240.00
934.00
605.00
Operating Expense
345,282.00
361,986.00
350,857.00
331,214.00
210,825.00
Operating Income
-344,980.00
-361,364.00
-350,617.00
-330,280.00
-210,220.00
Net Non Operating Interest Income Expense
-136,130.00
-128,335.00
-60,807.00
-14,013.00
-7,349.00
Other Income Expense
-120,329.00
-94,193.00
-5,862.00
-5,546.00
-8,464.00
Pretax Income
-601,439.00
-583,892.00
-417,286.00
-349,839.00
-226,033.00
Tax Provision
-40.00
-40.00
34.00
9.00
-1,846.00
Net Income Common Stockholders
-600,962.00
-583,196.00
-416,567.00
-346,790.00
-221,851.00
Diluted NI Available to Com Stockholders
-600,962.00
-583,196.00
-416,567.00
-346,790.00
-221,851.00
Basic EPS
-1.08
-1.15
-1.04
-0.89
-0.58
Diluted EPS
-1.08
-1.15
-1.04
-0.89
-0.58
Basic Average Shares
569,748.04
508,635.59
399,900.37
389,234.16
383,179.38
Diluted Average Shares
569,748.04
508,635.59
399,900.37
389,234.16
383,179.38
Total Operating Income as Reported
-345,866.00
-362,250.00
-351,298.00
-330,280.00
-220,880.00
Total Expenses
345,282.00
361,986.00
350,857.00
331,214.00
210,825.00
Net Income from Continuing & Discontinued Operation
-600,962.00
-583,196.00
-416,567.00
-346,790.00
-221,851.00
Normalized Income
-519,372.43
-533,137.43
-423,255.93
-343,542.96
-212,831.74
Interest Income
739.00
863.00
2,708.00
836.00
1,725.00
Interest Expense
136,869.00
129,198.00
63,515.00
14,849.00
9,074.00
Net Interest Income
-136,130.00
-128,335.00
-60,807.00
-14,013.00
-7,349.00
EBIT
-464,570.00
-454,694.00
-353,771.00
-334,990.00
-216,959.00
EBITDA
-446,184.00
-436,182.00
-335,511.00
-320,752.00
-204,220.00
Reconciled Depreciation
18,386.00
18,512.00
18,260.00
14,238.00
12,739.00
Net Income from Continuing Operation Net Minority Interest
-600,962.00
-583,196.00
-416,567.00
-346,790.00
-221,851.00
Total Unusual Items Excluding Goodwill
-81,595.00
-50,062.00
8,467.00
-4,448.00
-9,092.00
Total Unusual Items
-81,595.00
-50,062.00
8,467.00
-4,448.00
-9,092.00
Normalized EBITDA
-364,589.00
-386,120.00
-343,978.00
-316,304.00
-195,128.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-5.43
-3.43
1,778.07
-1,200.96
-72.74
12/31/2020 - 7/28/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IOVA Iovance Biotherapeutics, Inc.
10.35
+1.07%
 
CADL Candel Therapeutics, Inc.
11.98
+4.17%
 
ALT Altimmune, Inc.
8.04
+0.37%
 
SAVA Cassava Sciences, Inc.
22.10
-4.43%
 
RXRX Recursion Pharmaceuticals, Inc.
9.78
+3.82%
 
VKTX Viking Therapeutics, Inc.
67.52
+0.77%
 
JAGX Jaguar Health, Inc.
0.1686
-34.78%
 
ACIU AC Immune SA
3.1600
-0.63%
 
ARQT Arcutis Biotherapeutics, Inc.
9.35
+1.63%
 
ANVS Annovis Bio, Inc.
8.75
+5.29%